Edwards Lifesciences Corporation offers technologies that treat structural heart disease and critically ill patients. The company develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting. Edwards Lifesciences’ products and technologies are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care.
As a healthcare company, Edwards Lifesciences’ improvement in its product quality and safety performance is of great reputational importance and has the potential to increase the company’s competitiveness as well as reduce product recall related expenses which impact operating margins. Edwards has also demonstrated impressive improvements in its disclosures, recently publishing its first detailed Sustainability Report. In this report, the company discusses its approach to product innovation including product material reductions, conflict minerals and chemical management. Edwards also provides insight to its supply chain management and efforts to reduce its overall environmental footprint. Placing high value on its employees, the company offers comprehensive benefit packages, including a holistic approach to wellness, adoption assistance, back-up dependent care, home purchase support and discounted stock ownership. Furthermore, Edwards Lifesciences offers extensive training, and education opportunities for employees through Edwards University, while offering tuition assistance for outside institutions.
While Edwards Lifesciences has shown noticeable improvement in product quality and safety practices, the company lacks a specific board committee on product safety and quality.
Industry: Health Care
Country: United States
To the best of our knowledge the above information is accurate and was obtained from sources we believe to be reliable. Neither the information presented above nor any opinion expressed shall be construed as an offer to sell or a solicitation to buy the security. The views expressed are those of portfolio management as of 3/31/2017 and may not reflect current opinions or subsequent events.